Eli Lilly reported top-line Phase 3 results for retatrutide (Triumph-1), showing up to 28% average body-weight loss over 80 weeks in people with obesity, with different dosing arms meeting primary and key secondary endpoints. The trial enrolled 2,339 participants with obesity and a non-diabetic complication, including cardiovascular disease or high blood pressure. Weight loss averaged 28.3% in the 12 mg arm, 26% at 9 mg, and 19% at 4 mg, versus 2% on placebo. Lilly also reported gastrointestinal adverse events consistent with the class, including nausea/diarrhea and vomiting in portions of patients. The company framed the dataset as competitive with—and potentially benchmark-setting for—other obesity programs. The Phase 3 readout reinforces retatrutide’s triple-hormone design (GIP/GLP-1/glucagon targets) and keeps the US obesity approval pathway on track as Lilly prepares additional presentations and regulatory steps.